The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...
Berry and colleagues from the Institute for Healthcare Improvement and Henry Ford Health Detroit argue that deep, ...
In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback